Addition of the BCL2 inhibitor venetoclax to endocrine therapy does not improve clinical benefit in patients with ER-positive, HER2-negative, locally advanced/metastatic breast cancer, according to the primary analysis of the...
Read MoreFirst results of the randomized, phase 3 CheckMate 648 study demonstrate superior overall survival of first-line treatment with nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone. Standard...
Read MoreA 2-year update of the CheckMate 9LA trial shows sustained benefit of first-line treatment with nivolumab plus ipilimumab plus 2 cycles of chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung...
Read MoreAddition of 177Lu-PSMA-617 therapy to standard of care for patients with metastatic castration-resistant prostate cancer (mCRPC) significantly improves survival, according to results from the randomized, phase 3 VISION trial....
Read MoreRBN-2397 is a potent, selective inhibitor of PARP7 that could potentially release the brake on the antitumor immunity, is well tolerated, and demonstrated proof of mechanism in a first-in-human trial. Targeting cytosolic nucleic...
Read MoreFirst results of the GAIN/iCAT2 Consortium trial show the importance of molecular profiling of solid tumors in young patients. Next generation sequencing (NGS) assays are now a standard part of clinical care for many adult solid...
Read More
“Large-volume IV smart pumps are probably one of the most ubiquitous devices in acute care in the...
Read More
T2D self-management education and support (DSMES) provides patients with critical information and...
Read More
To optimize the management of diabetes, the long-term risks of associated complications must be...
Read More
“Obesity is an important comorbidity in psoriatic arthritis (PsA). While this is commonly assessed...
Read More
Q: I have a patient that I have been seeing for quite a while for MS. After some pretty good years...
Read MoreSignificant improvements in mortality among non-small cell lung cancer (NSCLC) cancer patients have been reported over the past 2 decades, according to Surveillance, Epidemiology, and End Results Program (SEER) data. The timing...
Read MoreLiquid biopsies based on circulating tumor DNA (ctDNA) analysis are being investigated for detection of residual disease and recurrence in patients with early-stage non-small cell lung cancer (NSCLC). Due to low ctDNA levels in...
Read MoreHerpes zoster (HZ) is prevalent in patients with Chronic Lymphocytic Leukemia (CLL) and affects younger patients who require chemotherapy. The risk of developing HZ increases in recipients of first and second line chemotherapy....
Read MoreSurvival is significantly improved by calendar period among patients diagnosed after 2004 and treated in the era of advanced therapies. Females and younger patients had a higher probability of long term survival. The survival of...
Read MoreA 24-month phone and app/web-based diet and physical activity intervention that was successful for weight loss in the general population did not result in greater weight loss or improvement in cardiovascular (CV) risk factors...
Read MoreThis study demonstrated for the first time that human peripheral blood mononuclear cells (PBMCs) from chronic lymphocytic leukemia (CLL) patients can be converted into NK cells, CD8+ T cells, NKT cells, and TCRγδ T cells...
Read MorePalliative care and coping in patients with acute myeloid leukemia receiving intensive induction therapy: A mediation analysis of data from a randomized trial. Integrated palliative and oncology care (IPC) as part of...
Read MoreProgression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with...
Read MoreEvidence indicates that balancing treatment efficacy with complication risk is critically important for older adults with non-Hodgkin’s lymphoma (NHL); however, the survival outcomes, rates of toxicities, and healthcare...
Read More
